The Metabo-oncology Company
Metabo-oncology — which focuses on the link between cancer and metabolic hormone dysfunction — is poised to spark a paradigm shift in cancer treatment.
Cancer and obesity are closely linked, yet little attention is paid to these patients and their special needs. SynDevRx – the leader in this emerging and important field – is changing that.
-
Treating Cancer and Metabolic Hormone Dysfunction
It’s a fact: People with metabolic hormone dysfunction, which is common in obese and overweight individuals or people with excess belly fat, are more likely to get — and die from — cancer. At least 10 tumor types, representing about 20 percent of U.S. cancer cases, are considered to be sensitive to key metabolic hormones.
No novel therapy is available for the metabo-oncology patient population. But SynDevRx is working on it.
-
Liver Cancer
Men with a body mass index (BMI) between 35 and 39.9 were found to have a 4.52-fold (i.e. 352%) increase in the relative risk of death from liver cancer (Calle et al, 2003, New Eng J Med, 348(17):1625-38). In the same study, women with a body mass index (BMI) between 35 and 39.9 were found to have a 1.68-fold (i.e. 68%) increase in the relative risk of death from liver cancer.
Increased risk of death from cancer when obese:
-
Breast Cancer
Post-menopausal women with a body mass index (BMI) between 30 and 34.9 were found to have a 1.6-fold (i.e. 60%) increase in the relative risk of death from breast cancer (Calle et al, 2003, New Eng J Med, 348(17):1625-38). In the same study, women with a body mass index (BMI) between 35 and 39.9 were found to have a 1.7-fold (i.e. 70%) increase in the relative risk of death from breast cancer, and women with a BMI ≥ 40 had a 2.1-fold (i.e. 112%) increase in the relative risk of death from breast cancer.
Increased risk of death from cancer when obese:
-
Pancreatic Cancer
Men with a body mass index (BMI) between 35 and 39.9 were found to have a 1.49-fold (i.e. 49%) increase in the relative risk of death from pancreatic cancer (Calle et al, 2003, New Eng J Med, 348(17):1625-38). In the same study, women with a body mass index (BMI) between 35 and 39.9 were found to have a 1.41-fold (i.e. 41%) increase in the relative risk of death from pancreatic cancer, while women with a BMI ≥ 40 had a 2.76-fold (i.e. 176%) increase in the relative risk of death from pancreatic cancer.
Increased risk of death from cancer when obese:
-
Uterine (endometrial) Cancer
Women with a body mass index (BMI) between 30 and 34.9 were found to have a 2.53-fold (i.e. 153%) increase in the relative risk of death from uterine/endometrial cancer (Calle et al, New Eng J Med; 2003, 348(17):1625-38). In the same study, women with a body mass index (BMI) between 35 and 39.9 were found to have a 2.77-fold (i.e. 177%) increase in the relative risk of death from uterine/endometrial cancer, while women with a BMI ≥ 40 had a 6.25-fold (i.e. 525%) increase in the relative risk of death from uterine/endometrial cancer.
Increased risk of death from cancer when obese:
-
Ovarian Cancer
Women with a body mass index (BMI) between 30 and 34.9 were found to have a 1.16-fold (i.e. 16%) increase in the relative risk of death from ovarian cancer (Calle et al, New Eng J Med; 2003, 348(17):1625-38). In the same study, women with a body mass index (BMI) between 35 and 39.9 were found to have a 1.51-fold (i.e. 51%) increase in the relative risk of death from ovarian cancer. A more recent meta-analysis of nine studies found that women who were obese (BMI ≥ 30) had a 1.17-fold (i.e. 17%) increase in risk of dying from ovarian cancer (Nagle et al, British J Cancer, 2015; 113:817–26.
Increased risk of death from cancer when obese:
-
Colorectal Cancer
Men with a body mass index (BMI) between 35 and 39.9 were found to have a 1.84-fold (i.e. 84%) increase in the relative risk of death from colorectal cancer while women with a body mass index (BMI) between ≥ 40 were found to have a 1.46-fold (i.e. 46%) increase in the relative risk of death from colorectal cancer (Calle et al, New Eng J Med; 2003, 348(17):1625-38).
Increased risk of death from cancer when obese:
-
Esophageal Cancer
Men with a body mass index (BMI) between 30 and 34.9 were found to have a 1.28-fold (i.e. 28%) increase in the relative risk of death from esophageal cancer while men with a body mass index (BMI) between 35 and 39.9 were found to have a 1.63-fold (i.e. 63%) increase in the relative risk of death from esophageal cancer (Calle et al, New Eng J Med; 2003, 348(17):1625-38). In this study there was no statistically significant increase in the relative risk of death from esophageal cancer in women with increased BMI.
Increased risk of death from cancer when obese:
